{"id":1153,"date":"2021-06-06T20:58:33","date_gmt":"2021-06-06T18:58:33","guid":{"rendered":"https:\/\/imi-pharma.com\/?page_id=1153"},"modified":"2021-06-15T11:11:37","modified_gmt":"2021-06-15T09:11:37","slug":"neurologji","status":"publish","type":"page","link":"https:\/\/imi-pharma.com\/english\/?page_id=1153","title":{"rendered":"Neurologji"},"content":{"rendered":"

[vc_row][vc_column width=”1\/2″][vc_custom_heading text=”Neurologji”][vc_column_text]<\/p>\n

S\u00ebmundjet kronike progresive, ve\u00e7an\u00ebrisht ato t\u00eb sistemit imunitar ndikojn\u00eb tek njer\u00ebzit – fizikisht, mend\u00ebrisht dhe shoq\u00ebrisht. Ne i vendosim nevojat e pacient\u00ebve n\u00eb qend\u00ebr t\u00eb gjith\u00e7kaje q\u00eb b\u00ebjm\u00eb, nga p\u00ebrkushtimi yn\u00eb te sigurimi i produkteve me cil\u00ebsi t\u00eb lart\u00eb deri te p\u00ebrpjekjet tona p\u00ebr rritjen e nd\u00ebrgjegj\u00ebsimit p\u00ebr s\u00ebmundjen.<\/p>\n

Udh\u00ebtimi p\u00ebr trajtimin e MS mund t\u00eb jet\u00eb sfidues p\u00ebr njer\u00ebzit q\u00eb jetojn\u00eb me MS dhe ne synojm\u00eb ta b\u00ebjm\u00eb p\u00ebrvoj\u00ebn sa m\u00eb pa stres p\u00ebr ta. Kjo \u00ebsht\u00eb arsyeja pse ne zhvillojm\u00eb opsione q\u00eb synojn\u00eb uljen e barr\u00ebs s\u00eb trajtimit, p\u00ebrmir\u00ebsimin e aderimit dhe b\u00ebrjen e administrimit m\u00eb t\u00eb p\u00ebrshtatsh\u00ebm. P\u00ebr ta b\u00ebr\u00eb k\u00ebt\u00eb me sukses, ne vazhdojm\u00eb t\u00eb zgjerojm\u00eb kuptimin ton\u00eb p\u00ebr sfidat e p\u00ebrgjithshme dhe nevojat e pacient\u00ebve, si dhe t\u00eb nxisim debatin midis komunitetit t\u00eb MS n\u00eb nj\u00eb p\u00ebrpjekje p\u00ebr t\u00eb p\u00ebrmir\u00ebsuar rezultatet e kujdesit<\/p>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/2″][vc_custom_heading text=”Neurology”][vc_column_text]<\/p>\n

Chronic progressive diseases, particularly those of the immune system impact people \u2013 physically, mentally and socially. We put patient needs at the center of everything we do, from our dedication to providing high quality products to our disease awareness-raising efforts.<\/p>\n

The MS treatment journey can be challenging for people living with MS, and we aim to make the experience as stress-free as possible for them. That is why we develop options aimed at lessening treatment burden, improving adherence and making administration more convenient. In order to do this successfully, we continue to expand our understanding of the overall challenges and needs of patients as well as foster debate amongst the MS community in an effort to improve care outcomes<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator][\/vc_column][\/vc_row][vc_row][vc_column][home_blog style=”grid” posts_per_page=”25″ dynamic_from_where=”cat” dynamic_cat=”18″][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column width=”1\/2″][vc_custom_heading text=”Neurologji”][vc_column_text] S\u00ebmundjet kronike progresive, ve\u00e7an\u00ebrisht ato t\u00eb sistemit imunitar ndikojn\u00eb tek njer\u00ebzit – fizikisht, mend\u00ebrisht dhe shoq\u00ebrisht. Ne i vendosim nevojat e pacient\u00ebve n\u00eb qend\u00ebr t\u00eb gjith\u00e7kaje q\u00eb b\u00ebjm\u00eb, nga p\u00ebrkushtimi yn\u00eb te sigurimi i produkteve me cil\u00ebsi t\u00eb lart\u00eb deri te p\u00ebrpjekjet tona p\u00ebr rritjen e nd\u00ebrgjegj\u00ebsimit p\u00ebr s\u00ebmundjen. Udh\u00ebtimi p\u00ebr trajtimin […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1153","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages\/1153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1153"}],"version-history":[{"count":4,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages\/1153\/revisions"}],"predecessor-version":[{"id":1380,"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=\/wp\/v2\/pages\/1153\/revisions\/1380"}],"wp:attachment":[{"href":"https:\/\/imi-pharma.com\/english\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}